De Facto Controlling Shareholder HLB, HLB Genex Share Ownership Change Disclosure

HLB Genex (187420), a biotech and healthcare materials company, disclosed on June 23 that its de facto controlling shareholder HLB experienced changes in share ownership. The report states that HLB's specific securities holdings increased from 6.55 million shares as of March 19, 2026, to 7.27 million shares as of June 23, 2026, resulting in a slight decrease in ownership ratio from 19.72% to 19.55%. The total shares outstanding remained at 2.6 million. Detailed changes show HLB's convertible bond holdings rose from 3.94 million to 4.66 million shares, acquired at 2,220 won per share. HLB Genex's stock closed at 2,070 won on June 23, down 5.26% from the previous day. As of the latest financial report, HLB Genex has total assets of 135.8 billion won, liabilities of 81.1 billion won, equity of 54.7 billion won, revenue of 43.4 billion won, and net profit of 22.9 billion won. The company, listed on KOSDAQ since March 29, 2000, is a basic pharmaceutical materials manufacturer.